Charles Schwab Investment Management Inc. Acquires 15,042 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Charles Schwab Investment Management Inc. boosted its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 5.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 296,207 shares of the company’s stock after buying an additional 15,042 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.99% of Inspire Medical Systems worth $54,911,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. First Horizon Advisors Inc. grew its stake in shares of Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 124 shares in the last quarter. True Wealth Design LLC bought a new stake in Inspire Medical Systems in the third quarter valued at approximately $30,000. Farther Finance Advisors LLC boosted its holdings in shares of Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after buying an additional 139 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Inspire Medical Systems by 178.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock worth $66,000 after purchasing an additional 229 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its position in Inspire Medical Systems by 37.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock valued at $68,000 after buying an additional 100 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Inspire Medical Systems news, CTO John Rondoni sold 583 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.49, for a total value of $99,395.67. Following the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Randy Ban sold 25,584 shares of Inspire Medical Systems stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the sale, the insider now owns 7,259 shares in the company, valued at $1,332,026.50. This trade represents a 77.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,225 shares of company stock worth $4,806,530 over the last ninety days. Corporate insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on INSP shares. Royal Bank of Canada reiterated an “outperform” rating and set a $260.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, February 11th. Morgan Stanley decreased their price objective on Inspire Medical Systems from $230.00 to $220.00 and set an “overweight” rating on the stock in a report on Tuesday, February 11th. Wells Fargo & Company cut their price objective on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. Piper Sandler cut their price objective on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. Finally, KeyCorp restated an “overweight” rating and set a $234.00 price target (down from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $228.82.

Inspire Medical Systems Stock Down 2.4 %

Shares of NYSE INSP opened at $158.65 on Friday. The business has a fifty day simple moving average of $185.65 and a two-hundred day simple moving average of $192.17. The firm has a market cap of $4.71 billion, a PE ratio of 91.70, a price-to-earnings-growth ratio of 2.86 and a beta of 1.48. Inspire Medical Systems, Inc. has a twelve month low of $123.00 and a twelve month high of $257.40.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 8.19% and a net margin of 6.67%. On average, research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.